The Phase 2 clinical trial, sponsored by Pontificia Universidad Catolica de Chile, aims to evaluate the immunogenicity superiority of booster doses with Omicron and trivalent vaccines compared to the CoronaVac vaccine in a population previously vaccinated against SARS-CoV-2. Given the ongoing need for effective COVID-19 vaccines, particularly against emerging variants, this trial addresses a significant market demand. The results could position the Omicron and trivalent vaccines favorably against existing competitors, particularly in regions with high CoronaVac usage. The trial's completion in October 2023 allows for timely data analysis and potential market entry, contingent on favorable outcomes. The collaboration with Sinovac Life Sciences Co., Ltd. suggests a strategic partnership that may enhance distribution and commercialization efforts.